Chapter 2 Summary and Highlights
Chapter 3 Disease Background and Overview
- Introduction
- What is Cancer?
- Cancer Drivers
- Cancer Staging
- Disease Background
- Brain Tumor Statistics
- Human Brain Function
- Causes of Tumor Development
- Mechanism of Tumorigenesis
- Types and Classification of Brain Tumors
- Diagnosis of Brain Tumors
- Magnetic Resonance Imaging (MRI)
- Magnetic Resonance Spectroscopy (MRS)
- Tissue Sampling/Biopsy/Surgical Removal of Tumor
- Computed Tomography (CT)
- Positron Emission Tomography (PET) or PET-CT Scan
- Cerebral Arteriogram
- Lumbar Puncture or Spinal Tap
- Myelogram
- Molecular Testing
- Neurological, Vision and Hearing Tests
- Neurocognitive Assessment
- Electroencephalography (EEG)
- Evoked Potentials
- Recurrence of Brain Tumors and Management
- Brain Tumor Metastases and Management
- Cognitive Challenges
- Pain Management
- Treatment Modalities
- Surgery
- Neurosurgery
- Emerging Treatments in Neurosurgery
- Radiotherapy
- New and Emerging Treatments in Neuro-radiotherapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
Chapter 4 Market Dynamics
- Introduction
- Market Drivers
- Increasing Global Incidence of Brain Cancer
- Early Cancer Detection
- Research Initiatives
- R&D Collaborations
- Increase in Oncology Spending
- Accelerated Approvals for Drugs Used in Rare Diseases
- Market Restraints
- Lack of Effective Treatment Options for Brain Tumors
- High Cost
- Low Screening
- Current Market Trends
- Immunotherapy
- Combination Therapy
- MRI-Guided Laser Surgery
- Palliative Therapy
- 3D Radiation Therapy
- Precision Medicine and Companion Diagnostics
- Polymer Wafer Implants
- Tumor Treating Fields (TTF)
Chapter 5 Market Breakdown by Therapy
- Introduction
- Chemotherapy
- Overview
- Principle of Chemotherapy
- BBB and Chemotherapy
- Chemotherapeutic Agents
- Side Effects of Chemotherapy
- New Developments
- Market Overview
- Market Size and Forecast
- Targeted Therapy
- Introduction
- Precision Medicine in Cancer
- Types and Methods of Targeted Therapy
- Drug Delivery Systems for Targeted Therapeutics
- FDA-Approved Targeted Therapeutics
- New Developments
- Market Overview
- Market Size and Forecast
- Immunotherapy
- Introduction
- Immunotherapeutic Agents
- New Developments
- Market Overview
Chapter 6 Market Breakdown by Patient Age
- Introduction
- Overview
- Treatment Options
- Market Overview
- Market Size and Forecast
Chapter 8 Market Breakdown by Region
- Introduction
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 9 Emerging Technologies and Future Trends
- Introduction
- Cancer Vaccines
- Nanomedicine
- Stem Cell Therapy
- Photodynamic Therapy
- Focused Ultrasound Therapy
- Radiomics and Pathomics
- CRISPR
- Artificial Intelligence
- Advancements in Genomics and Personalized Medicine
Chapter 10 Clinical Research in Brain Tumor Therapeutics
- Introduction
- The Drug Development Process
- Drug Discovery
- Early Formulation Studies
- Pre-Clinical Safety Studies
- Clinical Trials
- Regulatory Review
- Post-Marketing Surveillance
- Research Initiatives
- Defeat GBM Research Collaborative
- Cancer Moonshot
- End Brain Cancer Initiative
- Brain Cancer Translational Research Initiative
- Pediatric Brain Tumor Initiative
- GLIOTRAIN
- GBM Agile
- Clinical Trials and Experimental Treatments
Chapter 12 Competitive Landscape and Market Strategies
- Introduction
- Major Players and Market Share Analysis
- Market Strategies Employed, by Major Players
- Research and Development
- Patent Exclusivity
- Mergers and Acquisitions (M&A)
- New Developments
- Porter's Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat from New Entrants
- Threat from Substitutes
- Market Competition
Chapter 13 Regulatory and Reimbursement Landscape
- Introduction
- Drug Development Regulations
- U.S.
- Canada
- Mexico
- Europe
- Asia Pacific
- ROW
- Reimbursement Landscape
Chapter 14 Company Profiles
- ASTRA ZENECA PLC
- Business Overview
- BRISTOL-MYERS SQUIBB CO.
- Business Overview
- Financial Information
- Products and Services
- Development and Strategies
- CURTANA PHARMACEUTICALS, INC.
- Business Overview
- DEL MAR PHARMACEUTICALS, INC.
- Business Overview
- EISAI CO. LTD.
- Business Overview
- EMCURE PHARMA
- Business Overview
- F. HOFFMANN-LA ROCHE LTD.
- Business Overview
- Financial Information
- Products and Services
- Development and Strategies
- Business Highlights
- FRESENIUS KABI ONCOLOGY LTD.
- Business Overview
- IMMUNOCELLULAR THERAPEUTICS LTD.
- Business Overview
- ITEOS THERAPEUTICS
- Business Overview
- KAZIA THERAPEUTICS LTD.
- Business Overview
- MERCK & CO., INC.
- Business Overview
- Financial Information
- Products and Services
- Development and Strategies
- Business Highlights
- NAVINTA LLC
- Business Overview
- NEXTSOURCE BIOTECHNOLOGY LLC
- Business Overview
- Products and Services
- Development and Strategies
- Business Highlights
- NORTHWEST BIOTHERAPEUTICS, INC.
- Business Overview
- NOVARTIS INTERNATIONAL AG
- Business Overview
- Financial Information
- Products and Services
- Development and Strategies
- Business Highlights
- TOCAGEN, INC.
- Business Overview
- UNITED THERAPEUTICS CORP.
- Business Overview
List of Tables
Summary Table: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
Table 1: WHO Grading of Brain Tumors
Table 2: WHO Grading of Select Brain Tumors
Table 3: Survival Rates for Common Adult Brain and Spinal Cord Tumors, 2017
Table 4: Brain Structures and Functions
Table 5: WHO Classification of Brain Tumors, 2016
Table 6: Karnofsky Performance Scale
Table 7: Specific Types of Brain Tumor Metastasis
Table 8: Parts of the Brain Related to Major Cognitive Functions
Table 9: Timeline of Significant Developments in Radiotherapy, 1898-2006
Table 10: Rare/Orphan Drug Criteria: Selected Regulatory Organizations
Table 11: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
Table 12: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 13: Dosage and Administration of Temozolomide for Brain Tumors
Table 14: Current Brain Tumor Clinical Trials: Temozolomide
Table 15: Current Brain Tumor Clinical Trials involving Lomustine
Table 16: Current Brain Tumor Clinical Trials involving Carmustine
Table 17: PCV Regimen: Brain Tumor Chemotherapy
Table 18: Global Market for Brain Tumor Chemotherapy, by Region, Through 2023
Table 19: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 20: Monoclonal Antibodies
Table 21: Small Molecule Monoclonal Antibodies
Table 22: Current Brain Tumor Clinical Trials involving Bevacizumab
Table 23: Current Brain Tumor Clinical Trials involving Everolimus
Table 24: Global Market for Brain Tumor Targeted Therapy, by Region, Through 2023
Table 25: Current Brain Tumor Clinical Trials: Immunotherapy
Table 26: Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2023
Table 27: Hereditary Factors: Pediatric Brain Tumors
Table 28: Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2023
Table 29: Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2023
Table 30: Global Market for Brain Tumor Therapeutics Market, by End User, Through 2023
Table 31: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, Through 2023
Table 32: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, Through 2023
Table 33: Global Market for Brain Tumor Therapeutics in Universities, by Region, Through 2023
Table 34: Global Market for Brain Tumor Therapeutics , by Region, Through 2023
Table 35: North American Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 36: European Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 37: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2023
Table 38: Drug Development
Table 39: Selected Current Phase I Brain Tumor Clinical Trials
Table 40: Selected Current Phase II Brain Tumor Clinical Trials
Table 41: Selected Current Phase III Brain Tumor Clinical Trials
Table 42: Patent Review of Novel Compounds and Drug Delivery in Brain Tumors, February 2017 to August 2018
Table 43: Patent Review of Therapeutic Agents for Brain Tumors, January 2017 to August 2018
Table 44: Patent Review of Combination Therapies in Brain Tumors, September 2017 to September 2018
Table 45: Patent Review of Immunotherapies for Brain Tumors, December 2016 to July 2018
Table 46: Patent Review of Diagnosis and Biomarkers in Brain Tumors, January 2017 to September 2018
Table 47: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 48: Current Orphan Drug Designations for Brain Tumors
Table 49: Bristol-Myers Squibb: Revenue 2016 and 2017
Table 50: Bristol-Myers Squibb: Brain Tumor Pharmaceuticals
Table 51: Opdivo Approvals, 2017
Table 52: F. Hofmann-La Roche: Revenue 2016 and 2017
Table 53: F. Hofmann-La Roche: Brain Tumor Pharmaceutical Drugs
Table 54: Merck & Co., Inc.: Revenue 2016 and 2017
Table 55: Merck & Co., Inc.: Brain Tumor Pharmaceutical Drugs
Table 56: NextSource Biotechnology LLC: Brain Tumor Therapeutics
Table 57: Novartis: Revenue 2016 and 2017
Table 58: Novartis: Brain Tumor Pharmaceuticals
Table 59: Important Acronyms Related to Brain Tumor Therapeutics Used in This Report
List of Figures
Summary Figure: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
Figure 1: Percentage Share of Global Cancer Incidence, by Type, 2018
Figure 2: Percentage Share of Global Cancer Incidence, by Region, 2018
Figure 3: Hallmarks of Cancer
Figure 4: Five Year Relative Survival at Diagnosis, by Stage, 2014-2018
Figure 5: Goals of Surgical Treatment for Brain Tumors
Figure 6: Global Expenditures on Oncology Drugs, by Country/Region, 2013-2017
Figure 7: Projected Global Expenditures on Oncology Drugs, by Country/Region, 2020
Figure 8: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
Figure 9: Global Market for Brain Tumor Chemotherapy, by Region, 2017-2023
Figure 10: Targeted Therapy Types
Figure 11: Global Market for Brain Tumor Targeted Therapy, by Region, 2017-2023
Figure 12: Global Market for Brain Tumor Therapeutics, by Patient Age, 2017-2023
Figure 13: Percentage Share of Common Adult Brain Tumor Incidence, by Type, 2017
Figure 14: Percentage Share of Common Pediatric Brain Tumor Incidence, 2017
Figure 15: Differences: Adult and Pediatric Brain Tumors
Figure 16: Etiology: Pediatric Brain Tumors
Figure 17: Global Market for Adult Brain Tumor Therapeutics, by Region, 2017-2023
Figure 18: Global Market for Pediatric Brain Tumor Therapeutics, by Region, 2017-2023
Figure 19: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, 2017-2023
Figure 20: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, 2017-2023
Figure 21: Global Market for Brain Tumor Therapeutics in Universities, by Region, 2017-2023
Figure 22: Global Incidence of Brain Tumors, 2018-2040
Figure 23: Global Market for Brain Tumor Therapeutics Market, by Region, 2017-2023
Figure 24: North American Incidence of Brain Tumors, 2018-2040
Figure 25: North American Market for Brain Tumor Therapeutics, 2017-2023
Figure 26: North American Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 27: European Incidence of Brain Tumors, 2018-2040
Figure 28: European Market for Brain Tumor Therapeutics, 2017-2023
Figure 29: European Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 30: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 31: Asia-Pacific Market for Brain Tumor Therapeutics, 2017-2023
Figure 32: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, 2017-2023
Figure 33: ROW Market for Brain Tumor Therapeutics, 2017-2023
Figure 34: Pharmaceutical Drug Development
Figure 35: Current Clinical Trials, by Phase, 2018
Figure 36: Major Market Players Share in Brain Tumor Therapeutics Market, 2017
Figure 37: NIH Funding for Brain Cancer R&D, 2016-2018
Figure 38: R&D Expenditure of Top 3 Players in Brain Tumor Therapeutics, 2017
Figure 39: Bargaining Power of Buyers in the Brain Tumor Therapeutics Industry
Figure 40: Bargaining Power of Suppliers in the Brain Tumor Therapeutics Industry
Figure 41: Threat from New Entrants in the Brain Tumor Therapeutics Industry
Figure 42: Threat from Substitutes in the Brain Tumor Therapeutics Industry
Figure 43: Market Competition in the Brain Tumor Therapeutics Industry
Figure 44: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 45: Bristol-Myers Squibb: Net Sales, by Region/Country, 2017
Figure 46: Bristol-Myers Squibb: R&D Expenditure, 2016 and 2017
Figure 47: Roche Top 5 Pharmaceutical Drugs, by Sales Revenue, 2017
Figure 48: Avastin: Sales Revenue, 2016 and 2017
Figure 49: F. Hofmann-La Roche: Revenue Share, by Business Segment, 2017
Figure 50: F. Hofmann-La Roche: Revenue, by Region, 2015-2017
Figure 51: Roche Product Pipeline, by Disease Area, 2017
Figure 52: Novartis: Net Sales, by Division, 2017
Figure 53: Novartis: Net Sales, by Region, 2017
